Monte Rosa Therapeutics (GLUE) Payables (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Payables of $7.9 million for Q1 2026, up 21.74% year-over-year from $6.5 million in Q1 2025, and up 122.54% quarter-over-quarter from $3.6 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Payables (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Payables history runs 7 years deep, the most recent figure standing at $7.9 million for Q1 2026.
- In Q1 2026, Payables rose 21.74% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $7.9 million (up 21.74% YoY), while the FY2025 annual figure was $3.6 million, down 79.38% from the prior year.
- Payables for Q1 2026 stood at $7.9 million, up from $3.6 million in the prior quarter.
- The five-year high for Payables was $17.2 million in Q4 2024, with the low at $3.6 million in Q4 2025.
- The 5-year median for Payables is $6.5 million (2025), against an average of $7.5 million.
- The sharpest annual moves came in 2022 and 2025: Payables surged 758.8% in 2022, then tumbled 79.38% in 2025.
- Monte Rosa Therapeutics' Payables stood at $7.9 million in 2022, then surged by 41.85% to $11.2 million in 2023, then soared by 54.37% to $17.2 million in 2024, then sank by 79.38% to $3.6 million in 2025, then soared by 122.54% to $7.9 million in 2026.
- Business Quant data shows GLUE's Payables at $7.9 million in Q1 2026, $3.6 million in Q4 2025, and $14.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 7.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.15 Mn |
| Mar 31, 2026 | 7.90 Mn |
| Dec 31, 2025 | 3.55 Mn |
| Sep 30, 2025 | 14.51 Mn |
| Jun 30, 2025 | 5.58 Mn |
| Mar 31, 2025 | 6.49 Mn |
| Dec 31, 2024 | 17.22 Mn |
| Sep 30, 2024 | 3.98 Mn |
| Jun 30, 2024 | 6.47 Mn |
| Mar 31, 2024 | 6.83 Mn |
| Dec 31, 2023 | 11.15 Mn |
| Sep 30, 2023 | 5.50 Mn |
| Jun 30, 2023 | 5.31 Mn |
| Mar 31, 2023 | 7.38 Mn |
| Dec 31, 2022 | 7.86 Mn |
| Sep 30, 2022 | 9.75 Mn |
| Jun 30, 2022 | 4.29 Mn |
| Mar 31, 2022 | 4.51 Mn |
| Dec 31, 2021 | 6.56 Mn |
| Sep 30, 2021 | 3.53 Mn |